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doi:10.1016/j.jtcvs.2006.07.037bjective: Current left ventricular assist devices are designed to provide full
emodynamic support for patients with end-stage failing hearts, but their use has
een limited by operative risks, low reliability, and device-related morbidity. Such
oncerns have resulted in minimum use of left ventricular assist devices for
estination therapy. We hypothesize that partial circulatory support, which could be
chieved with small pumps implanted with less-invasive procedures, might expand
he role of circulatory support devices for treatment of heart failure.
ethods: We examine the hemodynamic effects of partial left ventricular support
sing a previously described computational model of the cardiovascular system.
esults from simulations were validated by comparison with an in vivo hemody-
amic study.
esults: Simulations demonstrated that partial support (2-3 L/min) increased total
ardiac output (left ventricular assist device output plus native heart output) by more
han 1 L/min and decreased left ventricular end-diastolic pressure by 7 to 10 mm Hg
ith moderate-to-severe heart failure. Analyses showed that the hemodynamic
enefits of increased cardiac output and decreased left ventricular end-diastolic
ressure are greater in less-dilated and less-dysfunctional hearts. Both the relation-
hips between ventricular assist device flow and cardiac output and ventricular assist
evice flow and left atrial pressure predicted by the model closely approximated the
ame relationships obtained during hemodynamic study in a bovine heart failure
odel.
onclusions: Results suggest that a pump with a flow rate of 2 to 3 L/min could
eaningfully affect cardiac output and blood pressure in patients with advanced
ompensated heart failure. The development of small devices capable of high
eliability and minimal complications that can be implanted with less-invasive
echniques is supported by these findings.
ommonly used left ventricular assist devices (LVADs) are designe
provide full hemodynamic support for the end-stage failing heart at rest and
during exertion.1 With flow rate capacities ranging from 5 to 10 L/min
djust to the rate of venous return, these LVADs also provide profound left
entricular pressure and volume unloading, which, during prolonged use, resu
tructural and functional reverse remodeling.1,2 However, even modern LVADs a
elatively large, require a major surgical procedure for their insertion, and are
ssociated with significant morbidity and mortality, especially during long-term use
s an alternative to transplantation (ie, destination therapy).
Clinical experience with approaches such as cardiac resynchronization therapy
CRT)3,4 and -blockers5,6 suggests that a large number of patients with h
ailure might derive clinical benefit from partial hemodynamic support. By defini-
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CSPion, partial support could be provided by smaller pumps
ith lesser flow capacities. Use of smaller pumps could
ranslate into less-invasive insertion procedures, reduced
nergy requirements, and greater longevity. Such features
ould facilitate use of LVADs in patients with less-severe
eart failure than in current practice. However, little is
nown about the hemodynamic effects of partial ventricular
upport in patients with advanced heart failure that do not
equire full hemodynamic support. Thus knowing which
atients might be candidates for partial support, the poten-
ial for partial support to induce reverse remodeling, and the
nticipated long-term hemodynamic effects of partial sup-
ort when used as destination therapy are unknown.
We have previously described a computational model of
he cardiovascular system7 that offers the ability to simulate
arious degrees of heart failure. This model readily lends
tself to testing the effects of varying degrees of LVAD
upport over a range of conditions. The core of this simu-
ation has been used to define important physiologic prin-
iples and has been used successfully to prospectively pre-
ict the effects of proposed heart failure treatments.8-12 In
he present study we use this simulation to predict the
heoretic hemodynamic effects of partial LVAD support
ith an axial flow pump over a broad range of heart failure
tates. Initial experiments in animals with chronic heart
ailure are used to validate the basic aspects of the model.
aterials and Methods
heoretical Considerations
he hemodynamic effects of partial left ventricular support in
eart failure were modeled by using a previously described com-
utational model of the cardiovascular system.8-12 This model, the
arameter values input to the model and basic hemodynamic
ariables derived from computations under normal conditions, and
 increasingly severe states of heart failure are detailed in Appen-
ix E1 and Tables E1 and E2. The details of the equations
overning flow through a continuous-flow blood pump and how
his was interfaced with the cardiovascular system model are also
rovided in Appendix E1. A similar approach has been used
ecently to study the effect of weaning an LVAD on the workload
Abbreviations and Acronyms
CO  cardiac output
CRT  cardiac resynchronization therapy
EDP  end-diastolic pressure
LA  left atrium
LAP  left atrial pressure
LVAD  left ventricular assist device
LVEDP left ventricular end-diastolic pressure
VAD  ventricular assist devicen the native heart.13 (
2 The Journal of Thoracic and Cardiovascular Surgery ● Janualinical Simulations
series of simulated experiments was conducted with the cardiovas-
ular model simulating ventricular assist device (VAD) flow from the
eft atrium (LA) or left ventricle (LV) to a proximal portion of the
rterial tree. Pressure-volume loops were constructed, and left atrial
ressure (LAP), aortic flow, and mitral valve flow were determined
nder conditions of mild, moderate, and severe heart failure before
nd during LVAD support. Simulations were performed to demon-
trate the influence of VAD flow on cardiac output (CO) and left
entricular end-diastolic pressure (LVEDP). Finally, the effects of
arying pump preload and afterload on total CO, mean arterial pres-
ure, and LVEDP were analyzed.
n Vivo Comparison
odel simulations were compared with data obtained from an
cute bovine experiment conducted to characterize the hemody-
amics of partial support in the LA-to-peripheral artery configu-
ation (carotid artery). Cardiac dysfunction was induced in an
5-kg male Jersey breed calf by administration of 20 mg/kg of
onensin 8 days before the hemodynamic study.14 On the day of
he operation, anesthesia was induced with isoflurane, followed by
left thoracotomy through the fifth interspace. The animal was
nstrumented with ultrasonic flow probes (Transonic, Inc, Ithaca,
Y) placed on the pulmonary, brachiocephalic, and carotid arter-
es and on the descending aorta. Pressure was measured in the LA,
orta, and LV with high-fidelity pressure-sensing catheters (Millar
nstruments, Houston, Tex). A conductance catheter with a micro-
anometer tip (Millar Instruments) was introduced retrograde
rom the aortic arch into the LV.
After instrumentation, a MEDOS DeltaStream DP 1 LT (MEDOS
mbH, Langensebold, Germany) VAD was implanted in an LA-to-
eft carotid artery bypass configuration with a 30F atrial cannula and
n 8-mm graft (Bard Peripheral Vascular, Inc, Tempe, Ariz) for the
utflow cannula. Flows generated by the DeltaStream pump were the
ame as the range of flows possible with the miniature VAD modeled
n this study. Thirty-second data collections were performed at base-
ine and 5, 10, and 15 minutes after attainment of the target flow by
djusting pump speed. The target flow levels evaluated were 1, 2, and
L/min. After completion of data collection at each time point at each
arget flow, data were recorded at 5, 10, and 15 minutes after the pump
as turned off, with the LVAD circuit clamped.
After adjusting cardiovascular parameters to match end-
ystolic and end-diastolic volumes and pressures, CO and LAP
btained from the in vivo experiment in the calf with moderate-
o-severe heart failure were plotted against data obtained from the
ardiovascular model to demonstrate the validity of model predic-
ions for in vivo results. The animal used in this study received
umane care in accordance with the “Guide for care and use of
aboratory animals” (National Academy Press, 1996) and the
uidelines determined by the Institutional Animal Care and Use
ommittee of the University of Louisville.
esults
imulation of Varying Degrees of Compensated Heart
ailure
ardiovascular model parameters were set to simulate nor-
al and mild, moderate, and severe heart failure conditionsTable E2). Note that for each of the increasingly severe
ry 2007
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Pegree of heart failure, the intent was to simulate well-
ompensated patients with progressive left ventricular dila-
ation and loss of contractility. The purpose of the simula-
ions was not to simulate cardiogenic shock.
Pressure-volume loops generated for each of the condi-
ions are shown in Figure 1, A. The pressure-volume rela
ionships are typical for progressive heart failure, with the
eft ventricular end-diastolic pressure-volume relationship
xhibiting a progressive shift toward larger volumes,
hereas the slope of the end-systolic pressure-volume rela-
ionship decreases as the degree of heart failure progresses.
he rightward shift of the pressure-volume loop demon-
trates the increased dilation of the heart as it fails, and it is
his progressive dilation that is the hallmark of left ventric-
lar remodeling. End-diastolic pressure (EDP) increases as
he severity of the heart failure state progresses, a conse-
uence of salt and water retention and venoconstriction,
hich collectively result in an increase of total body
tressed blood volume.
The pressures and flow tracings at each of these levels of
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igure 1. A, Pressure-volume relationships for normal and vary-
ng degrees of heart failure conditions. LV, Left ventricular; CHF,
ongestive heart failure. B, Pressure and flow tracings for normal
nd varying degrees of heart failure. Extreme left shows tracing
n normal condition, with increasing degrees of failure progress-
ng from left to right. MVF, Mitral valve flow; AoF, aortic flow.eart failure are shown in Figure 1, B. Compared with fl
The Journal of Thoracormal values, aortic pressure and left ventricular systolic
ressure decrease, whereas LAP increases. Because of the
ecreased contractility of the failing heart, there is a de-
rease in aortic flow. The reduced CO is of course associ-
ted with decreased ventricular filling through the mitral
alve, with decreases in both active and passive peak filling
elocities. All of these results are consistent with clinically
bserved changes in hemodynamic signals exhibited by
atients with heart failure.
AD Support
hen the simulated VAD is set at 26,000 rpm (set to flow
pproximately 3 L/min) in an LA-to-aortic bypass config-
ration modeling partial left ventricular support, there is a
eftward shift, narrowing, and increased height (ie, in-
reased peak pressure) of the pressure-volume loop (Fig
, A). This signifies increased aortic and left ventric
eak systolic pressures, with concomitant decreases in
VEDP, left ventricular end-diastolic volume, and LAP.
hen the pump bypass is from the LV to the proximal
ortion of the arterial tree, the shape of the loop changes
loss of isovolumic phases because blood is withdrawn
ontinuously), and the degree of unloading (as indexed by
he reductions in end-diastolic volume and pressure) is
lightly greater (Figure 2, A).
With either configuration, flow through the aortic valve
ecreases during VAD support because the pump is drawing
lood from the LA or LV and returning it to the proximal
rterial tree, bypassing the left ventricular outflow tract
Figure 2, B). With the LV-to-peripheral artery configu
ion, flow through the aortic valve is very small. Mean flow
cross the mitral valve is reduced with the VAD withdraw-
ng blood from the LA. In contrast, transmitral flow is
ncreased when the VAD withdraws blood from the LV, a
eflection of the overall increase in CO. In both cases native
O was 3.4 L/min, which increased to 4.5 L/min with blood
ithdrawn from either the LA or LV. Similarly, mean aortic
ressure increased from the baseline value of 89 mm Hg to
13 mm Hg during VAD support with either configuration.
DP decreased from 27 mm Hg to 19 and 21 mm Hg with
lood withdrawn from the LV and LA, respectively. By
omparing the hemodynamic effect of partial support be-
ween left ventricular and left atrial blood withdrawal over
wide range of baseline conditions, we confirmed that there
re negligible differences in net blood flow or blood pres-
ure and only a 2- to 3-mm Hg effect on LVEDP. Thus
ecause the fundamental effects of partial support on overall
ardiovascular function are similar when blood is with-
rawn from the ventricle as from the atrium, for simplicity,
he remainder of the analysis focuses on withdrawal of
lood from the atrium.
Figure 3, A, shows how total CO (ie, the sum of 
ow plus flow from the LV through the aortic valve) varies
ic and Cardiovascular Surgery ● Volume 133, Number 1 23
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CSPs a function of VAD flow (obtained by progressively
ncreasing VAD speed). The y-axis intercept of these curves
epresents the CO without any VAD support. The slope of
his line was approximately 0.36 (a unitless number) in
ormal or mild heart failure and decreased to approximately
.27 in severe heart failure. Thus, for the case of mild heart
ailure, for every 1 L/min of VAD flow, total CO was
ncreased by 0.36 L/min. The less than 1:1 ratio between
hange in total CO and VAD flow is because the VAD
hunts blood away from the LV; with decreased filling,
ntrinsic left ventricular output is decreased through the
rank-Starling relationship. The change in slope indicates
hat the effect of VAD support on total CO is greater when
he heart is less dilated and less weak. Furthermore, the
ncrease in total output occurs with the additional benefit of
reduction in LVEDP (a reflection of reduced pulmonary
igure 2. A, Pressure-volume loop at baseline heart failure state
solid line), with pump on (simulation 26,000 rpm, 3 L/min flow)
nd withdrawing blood from the left atrium (dashed line), and
ithdrawing blood from the left ventricle (dotted line). LVD, left
entricular dysfunction; LA, left atrium; Ao, aorta; LVAD, left
entricular assist device; LVP, left ventricular pressure; LVV, left
entricular volume. B, Pressure and flow tracings with the pump
ff and on (approximately 26,000 rpm, 3 L/min flow) in left atrial
LA)–aortic (Ao) and left ventricular (LV)–aortic bypass configu-
ation. LVAD, Left ventricular assist device; MVF, Mitral valve
ow; AoF, aortic flow.enous pressure). The slope of the relation between VAD m
4 The Journal of Thoracic and Cardiovascular Surgery ● Januaow and EDP (Figure 3, B) increased in magnitude fro
1.3 in severe heart failure to 2.5 in mild heart failure.
hus with regard to both the increase in total output and
eduction in filling pressure, this model predicts that any
egree of partial support is hemodynamically more effective
n states of mild compared with severe heart failure.
Stressed volume was varied over a wide range, and
emodynamic parameters were recorded with the VAD on
at 26,000 rpm, approximately 3 L/min) or off under con-
itions simulating mild and severe heart failure (Figure 
xplore the effect of patient volume status on VAD perfor-
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igure 3. A, Total cardiac output (CO) as a function of ventricular
ssist device flow. The difference in the slope of the relationship
or mild and severe heart failure indicates that the effect of
artial ventricular assist device support on cardiac output is
reater when the heart is less dilated and weak. CHF, congestive
eart failure; LVAD, left ventricular assist device. B, Left ventric-
lar end-diastolic pressure (LV EDP) as a function of ventricular
ssist device flow, further substantiating that this model predicts
ny degree of partial support to be hemodynamically more effec-
ive in states of mild compared with severe heart failure. CHF,
ongestive heart failure; LVAD, left ventricular assist device.ance. As shown in Figure 4, A, for each setting of cardiac
ry 2007
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Punction, VAD support increased total output by approxi-
ately the same amount at any level of intrinsic CO. The
roportion of total output assumed by the VAD increased as
ntrinsic output decreased. Consistent with the results
iscussed above, the magnitude of the increase was
reater in mild compared with severe heart failure. In
ontrast to the effects on CO, the effect of VAD support
n LVEDP was nonlinear, having a greater effect at
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igure 4. A, Effect of patient volume status on ventricular assist
evice performance during mild and severe heart failure. At each
evel of heart failure, partial ventricular assist device support
ncreased total output by the same amount at any given intrinsic
ardiac output value. CO, Cardiac output; LVAD, left ventricular
ssist device; CHF, congestive heart failure. B, Effect of patient
olume status on left ventricular end-diastolic pressure (LV EDP)
ith ventricular assist device support during mild and severe
eart failure. The effect of partial ventricular assist device sup-
ort on LV EDP was nonlinear, having a greater effect at lower
nd-diastolic pressures. LVAD, Left ventricular assist device;
HF, congestive heart failure.ower EDPs (Figure 4, B ). m
The Journal of Thoracptimizing Hemodynamic Effects of VAD Support
s discussed earlier, the addition of partial left ventricular
upport shifts the pressure-volume loop leftward toward
ower volumes, with a decrease in intrinsic CO. Concomi-
antly, the VAD improves overall circulatory hemodynam-
cs with increases in total CO and mean arterial pressure and
significant decrease in LVEDP. The effects on preload and
fterload can be substantial and can be intentionally manip-
lated in the clinic to optimize the hemodynamic effective-
ess of partial hemodynamic support, as shown by the
ressure-volume loops shown in Figure 5. The loop sh
y the solid line depicts the baseline loop in moderate heart
ailure. When the VAD is turned on (26,000 rpm), the loop
hifts leftward, EDP decreases, and blood pressure increases
dashed line).
The effect on hemodynamic parameters is summarized in
igure 5, B. Total CO increases in response to VAD 
ort; the relative contributions of intrinsic left ventricular
utput and pump flow are shown by the solid and hatched
ars, respectively. On institution of afterload reduction
simulated by a decrease in arterial resistance), the loop
hifts further leftward (reduced EDP), blood pressure de-
reases, and the total output increases, with a greater pro-
ortion attributable to the pump. Because of the now sub-
tantial decrease of EDP, a safe but increased total body
uid status can be tolerated, and an increased EDP is
ossible (dashed-dotted line), potentially enabling reduc-
ions in diuretic dose. Increasing stressed volume to levels at
hich EDP is still clinically acceptable results in increased
otal CO, and the pump accounts for a substantial portion of
he flow. As a result of optimization of “medical treatment,”
O could be increased by approximately 2 L/min, and mean
rterial pressure could be increased by 13 mm Hg, whereas
DP is maintained at less than 20 mm Hg in this example.
he results presented in Figure 5 thus reveal the m
isms by which a partial-support VAD allows for optimi-
ation of hemodynamic conditions through simple medica-
ion adjustments.
n Vivo Comparison
o validate the cardiovascular model, we compared the
imulation data with data obtained from an acute in vivo
reparation of chronic heart failure. Parameter values for the
nd-diastolic and end-systolic pressure-volume relations
ere guided by volume measurements made at baseline in
he animal by using the conductance technique, as detailed
n the “Methods” section. LVEDP (approximately 25 mm
g) and left ventricular volume (approximately 223 mL) in
he bovine before the initiation of VAD support were sim-
lar to values listed in Table E3 for the moderate-to-s
eart failure conditions simulated in the computational
odel. Pressure and flow measurements were obtained at
ultiple levels of pump speed, yielding flows up to approx-
ic and Cardiovascular Surgery ● Volume 133, Number 1 25
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CSPmately 3 L/min. Both the relationship between VAD flow
nd CO and between VAD flow and LAP predicted by the
odel closely approximated the same relationships obtained
rom the in vivo experiment (Figure 6). These find
ould therefore justify the underlying assumptions and
implifications intrinsic to the model.
iscussion
mall pumps designed to flow at 2 to 3.5 L/min could
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igure 5. A, Demonstration of the effects of preload and afterload
anipulation to optimize the hemodynamic effectiveness of a
artial-support ventricular assist device. LVP, Left ventricular
ressure; CHF, congestive heart failure; LVAD, left ventricular
ssist device; LVV, left ventricular volume. B, Hemodynamic pa-
ameters with varying preload and afterload with and without
artial ventricular assist device support. LV EDP, Left ventricular
nd-diastolic pressure; MAP, mean arterial pressure; CO, cardiac
utput; CHF, congestive heart failure; LVAD, left ventricular assist
evice.otentially be used to provide partial hemodynamic support b
6 The Journal of Thoracic and Cardiovascular Surgery ● Januaor patients with heart failure. Some are less than 20 mm in
iameter, lending themselves to minimally invasive implan-
ation techniques. The present results demonstrate that flows
n the range provided by these small pumps can result in
ows sufficient to meaningfully affect CO and blood pres-
ure in patients with advanced compensated heart failure. In
he simulations we performed, partial support of approxi-
ately 3 L/min increased total CO by more than 1 L/min
nd decreased LVEDP by 7 to 10 mm Hg in patients with
oderate-to-severe heart failure. The effectiveness of this
egree of support was further enhanced when afterload and
reload were intentionally manipulated in a manner that can
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igure 6. A, In vivo relationship of pump output and total cardiac
utput. This relationship approximates the same relationship re-
ulting from the simulation. B, In vivo relationship between pump
utput and left atrial pressure (LAP). Note the similarity of the in
ivo relationship to the simulated relationship.e implemented in the clinical setting. In such a condition,
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PO could be increased by approximately 2 L/min, mean
rterial pressure could be increased by 13 mm Hg, and EDP
s maintained at less than 20 mm Hg.
Large-scale studies with -blockers5,6 and CRT3 provide
vidence that relatively subtle changes in contractility can
esult in clinically important benefits, such as increased
xercise tolerance and improved quality of life. A mechan-
cal device, such as was modeled in the present study,
apable of enhancing CO by more than 3 times the amount
rovided by CRT could be applied to patients with more
evere disease than currently being treated with CRT. The
oncept of which patients could benefit is shown in F
. There are a large number of patients in whom trea
ith optimal medications and devices, such as CRT, fails
ut who are not sufficiently compromised to receive an
VAD. It is for these patients that a partial-support VAD
ould be effective and beneficial.
The results of the present modeling study showed that
he hemodynamic benefits of partial support are greater in
earts that are less dilated and less dysfunctional. For a
iven heart structure and function (ie, for specified end-
iastolic pressure-volume relationship and end-systolic
ressure-volume relationship), a partial-support VAD, such
s that characterized by Figure E2, adds a relatively 
mount of flow over a broad range of native COs (Figu
uring exercise, intrinsic CO increases, even in patients
ith heart failure; according to the findings of Figur
artial support will add the same fixed amount of flow
igure 7. As the severity of disease increases from normal to
ew York Heart Association class III and IV and ultimately to
ardiogenic shock (CGS), the possible maximal cardiac output
ecreases from that capable of supporting full exertion to that
arely necessary to support life. Partial support fills the gap
etween patients needing small amounts of hemodynamic sup-
ort to meaningfully enhance exercise tolerance, such as can be
rovided by cardiac resynchronization therapy (CRT), and those
ith severe heart failure who require a device that fully assumes
he work of the heart. LVAD, Left ventricular assist device.ndependent of CO at any particular time or state of exer- b
The Journal of Thoract
).
,
ion. Similarly, patients with different body sizes will have
ifferent resting COs, but again the increment in total flow
rovided by a partial-support VAD is predicted to depend
n ventricular characteristics and not on the actual value of
ntrinsic CO.
In addition to improvement of blood pressure and CO,
hich improves end-organ perfusion and function, LVAD
upport induces reverse remodeling, including improvement
n intrinsic ventricular function.1 Reverse remodeling in
atients with LVADs is in part a result of pressure and
olume unloading of the failing heart and in part a result of
he improved neurohormonal milieu (eg, decreased cat-
cholamines, tumor necrosis factor , and brain natriuretic
eptide).1 Because the results of the present simulat
corroborated by experimental study) demonstrate such un-
oading, they suggest that partial support might result in
everse remodeling. If this is the case, we hypothesize that
s heart structure and function improve, cardiac assistance
rovided by a partial-support VAD would improve over
ime as the native heart contribution to flow increases. Such
ffects could be further enhanced by the introduction and
ose optimization of medications known to induce reverse
emodeling, such as angiotensin-converting enzyme inhibi-
ors, -blockers, and aldosterone inhibitors.
There are 2 possible cannulation sites for such pumps:
he LV or the LA. As shown in Figure 2, there is a re
ignificant difference in the effect of the inflow cannulation
ite on the shape and position of the resulting pressure-
olume loop. With left atrial cannulation, the loops shift
oward a slightly lower filling pressure and volume, but
eak pressure increases, and the loop is relatively thin (both
ndicating increased afterload). In contrast, with left ven-
ricular cannulation, there are more significant reductions in
lling pressure and volume, peak pressure is relatively
onstant, and minimum volume attained during the cardiac
ycle is also significantly decreased. Because myocardial
xygen consumption is related to the pressure-volume
rea,15 it is evident that myocardial oxygen consumpt
ould be decreased more if blood were to be withdrawn
rom the LV than from the LA. Although the effect on net
O is predicted to be essentially identical between the 2
ites of inflow cannulation, the greater reductions in preload
olume, preload pressure, and myocardial oxygen consump-
ion could possibly affect the rate and extent of reverse
emodeling achieved during partial support, in which case
everse remodeling would be predicted to be greater with
nflow cannulation of the LV.
One limitation of the model used is that no attempt has
een made to model a situation in which the pump would
ause left atrial collapse and suction. The occurrence of
uction and atrial collapse in such settings would reduce
ows and create other problems for the pump that are
eyond the scope of the present simulation.
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CSPIn summary, the results of this model analysis suggest
hat significant hemodynamic benefits can be achieved with
artial ventricular support in patients with heart failure. This
egree of support is predicted to be more beneficial in hearts
hat are less dilated and less dysfunctional. These data
urther suggest that if partial support can induce a degree of
everse remodeling, the effectiveness of partial support
ight improve over time. Development of small devices
hat can provide 2 to 3 L/min flow and be implanted with
inimally invasive techniques is thus encouraged by these
ndings. The clinical availability of such devices could
esult in a risk-reduced and cost-effective way to treat
atients with heart failure before they become critically ill.
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Pppendix E1
he cardiovascular system was modeled as shown by the electrical
nalog in Figure E1. The details of this model are pro
lsewhereE1,E2 and will be discussed here in brief. Ventricular and
trial pumping characteristics were represented by modifications
f the time-varying elastance (E[t]) theory of chamber contraction,
hich relates instantaneous ventricular pressure (P[t]) to instanta-
eous ventricular volume (V[t]). Thus for each chamber,
P(t) Ped(V) (1 e(t))Pes(V),
here
Ped(V) B (eA(VVo) 1)
Pes(V) Ees(V Vo),
nd
e(t) 1 ⁄ 2sin[( ⁄ Tmax)t ⁄ 2] 1 0 t 3 ⁄ 2 Tmax
1 ⁄ 2 e(t3⁄2Tmax)⁄	 t
 3 ⁄ 2 Tmax,
here Ped(V) is end-diastolic pressure as a function of volume,
es(V) is end-systolic pressure as a function of volume, Ees is
nd-systolic elastance, Vo is the volume axis intercept of the
nd-systolic pressure-volume relationship, A and B are parameters
f the end-diastolic pressure-volume relationship, Tmax is the point
f maximal chamber elastance, 	 is the time constant of relaxation,
nd t is the time during the cardiac cycle.
The systemic and pulmonary circuits are each modeled by
umped venous and arterial capacitances (Cv and Ca, respectively);
proximal characteristic resistance (Rc, also commonly called
haracteristic impedance), which relates to the stiffness of the
roximal aorta or pulmonary artery; a lumped arterial resistance
Ra); and a resistance to return of blood from the venous capaci-
ance to the heart (Rv, which is similar, although not identical, to
uyton’s resistance to venous returnE3). The heart valves permit
ow in only one direction through the circuit.
The total blood volume (Voltot) contained within each of the
apacitive compartments is divided functionally into 2 pools: the
nstressed blood volume (Volunstr) and the stressed blood volume
Volstr). Volunstr, sometimes referred to as the dead volume, is
efined as the maximum volume of blood that can be placed within
capacitive vessel without increasing its pressure to greater than 0
m Hg. The blood volume within the capacitive compartment inxcess of Volunstr is Volstr, so that Voltot  Volunstr  Volstr. The E
The Journal of Thoracicnstressed volume of the entire vascular system is equal to the sum
f the Volunstr of all the capacitive compartments; similarly, the
otal body stressed volume equals the sum of Volstr for all com-
artments.E4 The pressure within the compartment is assumed to
ncrease linearly with Volstr in relation to the compliance (C), as
ollows:
P Volstr ⁄ C
The LVAD was modeled as a continuous flow pump with
pproximately linear pressure-flow characteristics that varied with
ump speed, as shown in Figure E2. These data were ob
rom a real pump interfaced with a mock circulation using a
ater-glycerol solution (viscosity, 3.6 cp). The pump is a proto-
ype for a miniature pump designed to be used in a clinical study.
s shown, such a pump can generate flows of up to 3.5 L/min with
ts impeller spinning at 28,000 rpm (pressure head between 100
nd 150 mm Hg). As indicated in Figure E1, it could be sp
uring the simulation whether the LVAD withdrew blood from the
A or the LV. In either case, the blood was pumped to the
roximal portion of the arterial system.
The normal value of each parameter of the model was set to be
ppropriate for a 70- to 75-kg man (body surface area, 1.9 m2).
hese values, adapted from values in the literature,E1,E3-E5are
isted in Table E1. Table E2 shows the parameter values u
imulate varying degrees of heart failure (mild, moderate, and
evere). Values shown in Table E1 that do not appear in Ta
etained the normal parameter values as specified in Table E
Table E3 shows the resultant values for hemodynamic pa
ters at the varying degrees of heart failure defined as mild,
oderate, and severe.
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CSPFigure E1. Electrical analog modeling cardiovascular system.
Figure E2. Pressure-flow characteristics of pump modeled. The gray box demarcates clinically relevant operating
points for the pump.8.e2 The Journal of Thoracic and Cardiovascular Surgery ● January 2007
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PABLE E1. Normal parameter values
arameter group/name Symbol Units Values
ommon parameters
Heart rate HR min1 70
AV delay AVD ms 160
Total blood volume BVtot mL 5000
Stressed blood volume BVstress mL 950
Unstressed blood volume BVunstress mL 4050
eart RA RV LA LV
End-systolic elastance Ees mm Hg/mL 0.45 0.61 0.45 3
Volume axis intercept Vo mL 10 5 10 5
Scaling factor for EDPVR A mm Hg 0.44 0.35 0.44 1.3
Exponent for EDPVR B mL1 0.049 0.04 0.049 0.027
Time to end-systole Tmax Ms 125 200 125 200
Time constant of relaxation 	 ms 25 30 25 30
AV valve resistance Rav mm Hg · s/mL 0.0025 0.0025
irculation Pulmonary Systemic
Characteristic impedance Rc mm Hg · s/mL 0.03 0.04
Arterial resistance Ra mm Hg · s/mL 0.03 1.1
Venous resistance Rv mm Hg · s/mL 0.025 0.025
Arterial compliance Ca mL/mm Hg 13 1.5
Venous compliance Cv mL/mm Hg 8 70V, Atrioventricular; RA, right atrium; RV, right ventricle; LA, left atrium; LV, left ventricle; EDPVR, end-diastolic pressure-volume relationship.ABLE E2. Parameter values to simulate different degrees
f heart failure
Normal Mild Moderate Severe
R 70 80 80 80
tressed blood volume 650 650 1750 1750
V Ees 0.61 0.50 0.42 0.40
V A 0.35 0.25 0.15 0.10
30 50 70 90
V Ees 4.5 1.25 0.75 0.57
V A 1.3 0.53 0.16 0.05
ystemic Rc 0.03 0.04 0.04 0.04
ystemic Ra 0.8 1.1 1.2 1.4
ulmonic Rc 0.03 0.02 0.04 0.02
ulmonic Ra 0.03 0.02 0.04 0.04
ystemic Ca 1.5 1.0 1.0 1.0
ote that model parameter values not shown in this table retained normal
alues, as specified in Table E1. See Table E1 for definitions of
bbreviations.
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CSPABLE E3. Simulation variables at different degrees of compensated heart failure
arameter Units Normal Mild Moderate Severe
ardiac output L/min 5.0 4.0 3.6 3.4
troke volume mL 71.0 50.0 45.0 43.0
ight atrial pressure (mean) mm Hg 8.0 4.0 10.0 10.0
ulmonary artery pressure (S/D/M) mm Hg 27/11 (15) 25/14 (16) 37/22 (25) 39/24 (22)
eft atrial pressure (mean) mm Hg 8.0 12.0 19.0 22.0
ortic pressure (S/D/M) mm Hg 111/57 (82) 109/60 (81) 110/66 (85) 109/71 (89)
V end-diastolic pressure mm Hg 13 7 17 17
V end-diastolic volume mL 96 91 123 132
V ejection fraction % 68 50 36 32
V end-diastolic pressure mm Hg 15 18 25 27
V end-diastolic volume mL 98 137 192 237
V ejection fraction % 73 36 25 18
/D/M, systolic/diastolic/mean; RV, right ventricular; LV, left ventricular.8.e4 The Journal of Thoracic and Cardiovascular Surgery ● January 2007
